Investigation of the mechanism of nephrotoxicity of nux‐vomica by PTGS2/CYP2C9‐mediated arachidonic acid pathway and Jian Pi Tong Luo compound's protective effect
Biomedical Chromatography · 2024
DOI: 10.1002/bmc.5859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2024. Verfasst von Na Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Drug Safety Evaluation Centre, Heilongjiang University of Chinese Medicine, Harbin, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Kidney, Arachidonic Acid, Cyclooxygenase 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program, Natural Science Foundation of Heilongjiang Province of China.
Abstract (Originalsprache)
The clinical effectiveness of nux‐vomica in treating rheumatism and arthralgia is noteworthy; however, its nephrotoxicity has sparked global concerns. Hence, there is value in conducting studies on detoxification methods based on traditional Chinese medicine compatibility theory. Blood biochemistry, enzyme‐linked immunosorbent assay, and pathological sections were used to evaluate both the nephrotoxicity of nux‐vomica and the efficacy of the Jian Pi Tong Luo (JPTL) compound in mitigating this toxicity. Kidney metabolomics, using ultra‐high‐performance liquid chromatography–quadrupole‐time‐of‐flight–MS (UPLC–Q‐TOF–MS), was applied to elucidate the alterations in small‐molecule metabolites in vivo . In addition, network pharmacology analysis was used to verify the mechanism and pathways underlying the nephrotoxicity associated with nux‐vomica. Finally, essential targets were validated through molecular docking and western blotting. The findings indicated significant nephrotoxicity associated with nux‐vomica, while the JPTL compound demonstrated the ability to alleviate this toxicity. The mechanism potentially involves nux‐vomica activating the “PTGS2/CYP2C9–phosphatidylcholine–arachidonic acid metabolic pathway.” This study establishes a scientific foundation for the clinical use of nux‐vomica and lays groundwork for further research and safety assessment of toxic Chinese herbal medicines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Safety Evaluation Centre, Heilongjiang University of Chinese Medicine, Harbin, China.
- The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
- Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, China.
ORCID-Profile: Na Zhang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program
- Natural Science Foundation of Heilongjiang Province of China
- Postdoctoral Research Foundation of Heilongjiang Province
- Youth Science and Technology Innovation Foundation of Heilongjiang Traditional Chinese Medicine Association
- Doctoral Innovation Foundation of Heilongjiang University of Chinese Medicine
- National Key Research and Development Program of China
Zitieren
APA
Zhang, N., An, B., Zhao, L., Zhao, D., Lv, B., & Liu, S. (2024). Investigation of the mechanism of nephrotoxicity of nux‐vomica by PTGS2/CYP2C9‐mediated arachidonic acid pathway and Jian Pi Tong Luo compound's protective effect. Biomedical Chromatography. https://doi.org/10.1002/bmc.5859
Vancouver
Zhang N, An B, Zhao L, Zhao D, Lv B, Liu S. Investigation of the mechanism of nephrotoxicity of nux‐vomica by PTGS2/CYP2C9‐mediated arachidonic acid pathway and Jian Pi Tong Luo compound's protective effect. Biomedical Chromatography. 2024. doi:10.1002/bmc.5859
BibTeX
@article{Zhang2024,
author = {Zhang, Na and An, Baisong and Zhao, Liangyou and Zhao, Dapeng and Lv, Bochuan and Liu, Shumin},
title = {Investigation of the mechanism of nephrotoxicity of nux‐vomica by PTGS2/CYP2C9‐mediated arachidonic acid pathway and Jian Pi Tong Luo compound's protective effect},
journal = {Biomedical Chromatography},
year = {2024},
doi = {10.1002/bmc.5859}
}
EUVIMED